Current Assets
Cash, Cash Equivalents, and Marketable Securities
Amgen Cash, Cash Equivalents, and Marketable Securities increased by 34.7% to $11.48B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 38.3%, from $8.3B to $11.48B. Over 5 years (FY 2020 to FY 2025), Cash, Cash Equivalents, and Marketable Securities shows a downward trend with a -2.8% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
First reportedQ4 2017
Last reportedQ1 2026Apr 30, 2026
Metric ID:
cash_equivalents_marketable_securities_totalHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.16B | $12.28B | $7.3B | $5.85B | $6.41B | $10.92B | $4.34B | $31.07B | $33.62B | $34.21B | $10.4B | $9.24B | $8.81B | $8.58B | $11.49B | $8.3B | $7.49B | $8.71B | $8.53B | $11.48B |
| QoQ Change | — | +71.5% | -40.5% | -19.9% | +9.6% | +70.3% | -60.3% | +616.6% | +8.2% | +1.8% | -69.6% | -11.2% | -4.6% | -2.7% | +33.9% | -27.7% | -9.8% | +16.3% | -2.1% | +34.7% |
| YoY Change | — | — | — | — | -10.4% | -11.0% | -40.6% | +430.8% | +424.2% | +213.2% | +140.0% | -70.3% | -73.8% | -74.9% | +10.4% | -10.1% | -15.0% | +1.5% | -25.8% | +38.3% |
Range$4.34B – $34.21B
CAGR+10.5%
Avg YoY Growth+57.9%
Median YoY Growth-10.3%
Cash, Cash Equivalents, and Marketable Securities at Other Companies
Frequently Asked Questions
- What is Amgen's cash, cash equivalents, and marketable securities?
- Amgen (AMGN) reported cash, cash equivalents, and marketable securities of $11.48B in Q1 2026.
- How has Amgen's cash, cash equivalents, and marketable securities changed year-over-year?
- Amgen's cash, cash equivalents, and marketable securities increased by 38.3% year-over-year, from $8.3B to $11.48B.
- What is the long-term trend for Amgen's cash, cash equivalents, and marketable securities?
- Over 5 years (2020 to 2025), Amgen's cash, cash equivalents, and marketable securities has grown at a -2.8% compound annual growth rate (CAGR), from $9.85B to $8.53B.